June 20, 2019
AstraZeneca’s Bevespi Aerosphere approved in Japan for COPD patients
AstraZeneca’s Bevespi Aerosphere has been approved by the Japanese Ministry of Health, Labour and Welfare for patients with chronic obstructive pulmonary disease, becoming the first approved fixed-dose, long-acting dual bronchodilator in a pressurised metered-dose inhaler device in Japan.